Avelumab and Merkel Cell Carcinoma: Examining the Biological Plausibility of Causation

From General Health to Occupational Exposure

The legacy context of general health and science information has long emphasized the importance of understanding how lifestyle factors, including substance use, can influence overall well-being. Discussions around alcohol consumption during the pandemic, for instance, highlighted the need for balanced habits and awareness of potential health consequences. This foundational perspective on health maintenance and risk awareness provides a useful starting point for examining more specialized exposures. Transitioning from this broad health heritage, the focus now shifts to occupational and therapeutic exposure contexts. In mass production environments, workers may encounter a range of chemical agents, including pharmaceutical compounds such as Avelumab, a monoclonal antibody used in cancer treatment. Understanding the biological plausibility of any association between Avelumab exposure and Merkel Cell Carcinoma risk requires careful consideration of exposure pathways, dose-response relationships, and individual susceptibility factors. This occupational concern moves beyond general health advice to address specific, controlled exposures in industrial settings, where monitoring and risk assessment become paramount. The shift from population-level health guidance to workplace-specific exposure analysis underscores the need for precise, evidence-based approaches in occupational health.

Avelumab: Mechanism and Therapeutic Use

Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/29799096/). The approval was based on the JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, the biological plausibility of avelumab causing or contributing to the development of MCC must be examined carefully, as the drug is used therapeutically for this same cancer.

Etiology of Merkel Cell Carcinoma

MCC has two primary etiologies: approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385/). Avelumab, as an anti-PD-L1 inhibitor, works by blocking the PD-1/PD-L1 pathway, thereby enhancing the immune system's ability to recognize and attack tumor cells (https://pubmed.ncbi.nlm.nih.gov/29799096/). This mechanism is intended to treat MCC, not cause it. However, immune checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). These irAEs can include conditions such as sarcoidosis, as reported in a case of hypercalcaemia secondary to reactivation of sarcoidosis in a patient on avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). While such events demonstrate immune dysregulation, they do not directly implicate avelumab in causing de novo MCC.

Evidence for Causation: Lack of Support

The mechanistic pathways linking avelumab to MCC are not straightforward. The drug is used to treat MCC, and its efficacy is based on enhancing T-cell responses against the tumor (https://pubmed.ncbi.nlm.nih.gov/34445385/). However, approximately 50% of patients do not respond to immune checkpoint inhibitors or develop irAEs due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/). In avelumab-refractory patients, subsequent treatment with ipilimumab plus nivolumab has shown responses in some cases, indicating that resistance to avelumab does not preclude response to other checkpoint inhibitors (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). This suggests that avelumab does not cause MCC but rather that some tumors evade its effects. From a causation perspective, the timeline between avelumab exposure and documented harm is critical. In the JAVELIN Merkel 200 trial, avelumab was administered to patients with existing metastatic MCC, and responses were measured over time (https://pubmed.ncbi.nlm.nih.gov/29799096/). There is no evidence in the provided sources that avelumab induces new MCC in patients without pre-existing disease. Instead, the drug is used to treat established MCC. The adverse events reported are immune-related, such as sarcoidosis reactivation, which occurred during treatment and resolved with corticosteroids, allowing continuation of avelumab (https://pubmed.ncbi.nlm.nih.gov/31543781/). This indicates that while avelumab can cause immune-mediated harm, it does not cause MCC itself.

Risk Context and Adequacy of Warnings

Risk anchors regarding the adequacy of warnings for avelumab and MCC are relevant. The prescribing information for avelumab includes warnings about immune-related adverse events, but the provided sources do not specify warnings about causing MCC. Given that avelumab is approved specifically for MCC, the risk of causing the disease is not applicable; rather, the risk is that the drug may not be effective in some patients or may cause irAEs. For affected patients, causation considerations should focus on whether avelumab contributed to progression or lack of response, rather than causing the initial cancer. The timeline between exposure and harm is typically measured in weeks to months for irAEs, as seen in the sarcoidosis case (https://pubmed.ncbi.nlm.nih.gov/31543781/), but no evidence links avelumab to new MCC development. In summary, the biological plausibility of avelumab causing MCC is not supported by the available evidence. The drug is a treatment for MCC, and its mechanism of action is to enhance immune responses against the tumor. While it can cause immune-related adverse events, these do not include induction of MCC. The evidence indicates that avelumab is used in patients with existing MCC, and any harm is related to irAEs or lack of efficacy, not causation of the disease.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can Avelumab cause Merkel Cell Carcinoma?

No, the available evidence does not support that Avelumab causes Merkel Cell Carcinoma. Avelumab is a treatment for MCC, and its mechanism of action enhances immune responses against the tumor. While it can cause immune-related adverse events, these do not include induction of MCC. (https://pubmed.ncbi.nlm.nih.gov/29799096/)

What is the biological plausibility of Avelumab causing MCC?

The biological plausibility is low because Avelumab is designed to treat MCC by blocking PD-L1 and activating T-cells. There is no evidence that it initiates new MCC; rather, it is used in patients with existing disease. Immune-related adverse events are possible but do not involve causing MCC. (https://pubmed.ncbi.nlm.nih.gov/34445385/)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.